Ho See-Lok, Chan Ho-Man, Ha Amber Wai-Yan, Wong Ricky Ngok-Shun, Li Hung-Wing
Department of Chemistry, Hong Kong Baptist University , Kowloon Tong, Hong Kong, People's Republic of China.
Anal Chem. 2014 Oct 7;86(19):9880-6. doi: 10.1021/ac5025182. Epub 2014 Sep 23.
MicroRNAs (miRNAs) are small noncoding RNAs that regulate human gene expression at the post-transcriptional level. Growing evidence indicates that the expression profile of miRNAs is highly correlated with the occurrence of human diseases including cancers. Playing important roles in complex gene regulation processes, the aberrant expression pattern of various miRNAs is implicated in different types and even stages of cancer. Besides localizing in cells, many of these miRNAs are found circulating around the body in a wide variety of fluids such as urine, serum and saliva. Surprisingly, these extracellular circulating miRNAs are highly stable and resistant to degradation, and therefore, are considered as promising biomarkers for early cancer diagnostic via noninvasive extraction from body fluids. Unfortunately, the abundance of these small RNAs is ultralow in the body fluids, making it challenging to quantify them in complex sample matrixes. Establishing a sensitive, specific yet simple assay for an accurate quantification of circulating miRNAs is therefore desirable. Our group previously reported a sensitive and specific detection assay of miRNAs in single molecule level with the aid of total internal reflection fluorescence microscopy. In this work, we advanced the assay to differentiate the expression of a nasopharyngeal carcinoma (NPC) up-regulator hsa-mir-205 (mir-205) in serum collected from patients of different stages of NPC. To overcome the background matrix interference in serum, a locked nucleic acid-modified molecular beacon (LNA/MB) was applied as the detection probe to hybridize, capture and detect target mir-205 in serum matrix with enhanced sensitivity and specificity. A detection limit of 500 fM was achieved. The as-developed method was capable of differentiating NPC stages by the level of mir-205 quantified in serum with only 10 μL of serum and the whole assay can be completed in 1 h. The experimental results agreed well with those previously reported whereas the quantity of miR-205 determined by our assay was found comparable to that of quantitative reverse transcription polymerase chain reaction (qRT-PCR), supporting that this assay can be served as a promising noninvasive detection tool for early NPC diagnosis, monitoring and staging.
微小RNA(miRNA)是一类小的非编码RNA,可在转录后水平调节人类基因表达。越来越多的证据表明,miRNA的表达谱与包括癌症在内的人类疾病的发生高度相关。各种miRNA的异常表达模式在复杂的基因调控过程中发挥重要作用,与不同类型甚至癌症阶段都有关联。除了存在于细胞内,许多此类miRNA还在尿液、血清和唾液等多种体液中循环于体内。令人惊讶的是,这些细胞外循环miRNA高度稳定且抗降解,因此被视为通过从体液中无创提取进行早期癌症诊断的有前景的生物标志物。不幸的是,这些小RNA在体液中的丰度极低,这使得在复杂样品基质中对其进行定量分析具有挑战性。因此,建立一种灵敏、特异且简单的检测方法以准确量化循环miRNA是很有必要的。我们团队之前报道了借助全内反射荧光显微镜在单分子水平对miRNA进行灵敏且特异的检测方法。在这项工作中,我们改进了该检测方法,以区分从鼻咽癌(NPC)不同阶段患者血清中上调的鼻咽癌(NPC)调节因子hsa-mir-205(mir-205)的表达。为克服血清中的背景基质干扰,将锁核酸修饰的分子信标(LNA/MB)用作检测探针,以增强的灵敏度和特异性在血清基质中杂交、捕获和检测靶标mir-205。实现了500 fM的检测限。所开发的方法能够通过仅用10 μL血清定量的mir-205水平区分NPC阶段,整个检测可在1小时内完成。实验结果与先前报道的结果吻合良好,同时我们检测确定的miR-205量与定量逆转录聚合酶链反应(qRT-PCR)的结果相当,这支持该检测可作为用于早期NPC诊断、监测和分期的有前景的无创检测工具。